Is Champions Oncology about to turn this around?
 | By Ellen Johnson | Macroaxis Story |
Champions Oncology Debt to Equity Ratio is relatively stable at the moment as compared to the past year. Champions Oncology reported last year Debt to Equity Ratio of 2.90. As of 09/14/2020, Free Cash Flow per Share is likely to grow to 0.06, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (1.1 M). While many traders today are more concerned about the preservation of capital over market returns, Champions Oncology could be one exception. Why are we still confident in hope for a quick recovery. Here I will also expose some primary fundamental factors affecting Champions Oncology's services, and outline how it will impact the outlook for investors this year.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Rifka Kats
Champions Oncology reported the previous year's revenue of 32.12 M. Net Loss for the year was (1.98 M) with profit before overhead, payroll, taxes, and interest of 15.24 M. About 21.0% of the company shares are held by company insiders. Champions Oncology has Price/Earnings (P/E) ratio of 605.0. The entity recorded a loss per share of 0.17. The firm had not issued any dividends in recent years. Champions Oncology had 1:12 split on the 12th of August 2015. The performance of Champions Oncology in the marketplace will significantly impact your decision to invest in its stock. Revenue growth, profitability, competitive positioning, management quality, and industry trends can influence Champions Oncology's stock prices. When investing in Champions Oncology, there are several factors to consider and potential outcomes to expect. As a company performs well, its stock price may increase, allowing investors to benefit from price appreciation. However, Champions Stock can experience significant price fluctuations due to market conditions, economic factors, industry trends, or company-specific news. This is why investing in stocks such as Champions Oncology carries risks, including the potential for capital loss. Stock prices can decline, and investors may incur losses if they sell shares at a lower price than their initial investment.
How important is Champions Oncology's Liquidity
Champions Oncology financial leverage refers to using borrowed capital as a funding source to finance Champions Oncology ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Champions Oncology financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Champions Oncology's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Champions Oncology's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Champions Oncology's total debt and its cash.
Champions Oncology Gross Profit
Champions Oncology Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Champions Oncology previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Champions Oncology Gross Profit growth over the last 10 years. Please check Champions Oncology's gross profit and other fundamental indicators for more details.
Breaking down Champions Oncology Further
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Champions Oncology has an asset utilization ratio of 556.0 percent. This connotes that the company is making $5.56 for each dollar of assets. An increasing asset utilization means that Champions Oncology is more efficient with each dollar of assets it utilizes for everyday operations.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Champions Oncology. Please refer to our Terms of Use for any information regarding our disclosure principles.